Login to Your Account


It's best to take broad view early with focus on mutual wins

By Randy Osborne
Staff Writer

Thursday, September 15, 2016

BOSTON – In moving a startup along, "I don't think [valuation] is where you start," Sentien Biotherapeutics Inc. CEO Brian Miller told attendees of Biopharm America. "I think you have to almost end there."

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription